Trials / Completed
CompletedNCT01664039
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is evaluate effects of TRAVATAN® versus LUMIGAN® on intraocular pressure (IOP) and ocular surface and inflammatory biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Travoprost 0.004% ophthalmic solution | Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative |
| DRUG | Bimatoprost 0.01% ophthalmic solution | Ophthalmic solution containing benzalkonium chloride (BAK) |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2012-08-14
- Last updated
- 2015-08-03
- Results posted
- 2015-07-14
Source: ClinicalTrials.gov record NCT01664039. Inclusion in this directory is not an endorsement.